There is no GLP-1 in a GLP-1 patch. That is not a criticism of any particular seller; it is a statement about the category, and every product page we read on 2026-09-16 agrees with it. What is sold under the name is an adhesive square carrying botanical extracts and B vitamins, and the name is doing the work.
This page sets out what the regulators have said, what the chemistry allows, what the research record contains, and what is on the products themselves. Where a figure appears it carries its source and the date we read it. It does not tell anyone what to use; that belongs with a prescriber, as our editorial standards set out.
The regulator's position predates the product by a decade
In January 2014 the Federal Trade Commission published Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims, which lists seven claims the agency describes as scientifically impossible for a weight-loss product. The seventh is a claim of substantial weight loss from something worn on the body or rubbed on the skin, and the guide states the reasoning in one sentence:
"Weight loss is an internal metabolic process. Nothing you wear or apply to the skin can cause substantial weight loss."
The guide's own examples are body wraps, creams, belts and earrings. It was written eleven years before the phrase "GLP-1 patch" existed, which is worth noting: the FTC did not react to this category, the category walked into a position the FTC had already taken.
The FDA's page on unapproved GLP-1 drugs, current as of 2026-09-01, is narrower than people assume. It addresses compounded versions, counterfeits, and products sold online as "for research purposes" or "not for human consumption". It does not mention patches. The gap matters: the FDA statement most often cited alongside this topic is not actually about it.
The size problem, in numbers
Skin is a barrier, and the property that decides what crosses it is mostly size. The figure usually quoted as the practical ceiling is 500 daltons, from Bos and Meinardi's paper in Experimental Dermatology in June 2000 (doi:10.1034/j.1600-0625.2000.009003165.x, verified 2026-09-16). It is a rule of thumb rather than a law, but nothing in the literature moves it by an order of magnitude.
Here is where the GLP-1 molecules sit against it, read from PubChem on 2026-09-16:
| Molecule | Molecular weight | Multiple of the 500-dalton threshold |
|---|---|---|
| Liraglutide | 3,751 Da | 7.5× |
| Semaglutide | 4,114 Da | 8.2× |
| Tirzepatide | 4,813 Da | 9.6× |
A molecule eight times over the threshold does not cross skin slowly. It does not cross.
This is also why the honest version of the question is not "does the patch deliver enough semaglutide" but "does the patch contain any". On every product page we read, the answer given by the seller is no.
What the research record contains, and what it does not
We searched ClinicalTrials.gov on 2026-09-16. The results are short enough to print in full:
| Query | Studies returned | What they actually are |
|---|---|---|
transdermal tirzepatide |
0 | — |
transdermal semaglutide |
1 | A study of menopausal hormone therapy, in which the transdermal product is estradiol and the GLP-1 agonist is injected |
transdermal berberine |
0 | — |
semaglutide (positive control) |
782 | Semaglutide trials |
The last row is the control. A search interface returning 782 results for semaglutide and zero for transdermal tirzepatide is not failing to find the studies; the studies are not there.
The published laboratory work is more interesting than the absence suggests, and it argues the same way. Three papers have moved a GLP-1 agonist across skin:
- PNAS, April 2016 (113(15):4140-5). Researchers re-engineered exendin-4 into a new analogue, E6, specifically to make it potent enough to deliver in a tiny volume, then delivered it with a dissolvable microstructure system. A five-minute application improved glucose tolerance for 96 hours — in guinea pigs.
- Biology, May 2025 (14(5):575). Transdermal semaglutide reduced body weight in mice.
- AAPS PharmSciTech, July 2026. A dissolving microneedle system for semaglutide, a formulation-stability study.
Every one of them punctures the skin. Microneedle arrays work precisely because they bypass the barrier that the 500-dalton rule describes, which is an admission that the barrier is real. None of this work has reached a human trial, and none of it is an adhesive patch of the kind being sold.
The legal argument is the one most coverage misses
In August 2026, Annals of Pharmacotherapy published a short analysis by White, Tai and Nuzi at the University of Connecticut School of Pharmacy (60(8):813-816) that makes a point about the statute rather than the science.
The Dietary Supplement Health and Education Act defines a dietary supplement as a product intended for ingestion. A product you stick on your arm is not ingested. The authors' conclusion follows from the definition rather than from any finding about efficacy: a dietary supplement sold as a transdermal patch does not meet the statutory definition of a dietary supplement, so the entire category is, in their words, in violation of the law.
Their survey found:
- 24 transdermal patch dietary-supplement products and 1 transdermal gel
- an average of 7 ± 4 natural ingredients per product
- berberine, glutamine or glutamate, cinnamon and pomegranate the most frequently listed
- no certificates of analysis posted for any of them
- many products missing the FDA disclaimer
- several with one- and two-star reviews describing lack of effect or adverse events
That last absence is the one worth dwelling on. A certificate of analysis is how a supplement buyer checks that the contents match the label. Without one, a reader has no way to verify either that the listed ingredients are present or that unlisted ones are not.
What the sellers themselves say
Our reading of the live product pages is on a separate page, because it needs a table and it needs dating: what the patch brands claim, brand by brand. Two findings from it belong here.
First, nobody selling these products claims they contain a GLP-1 drug. The claims are of the "may support metabolism" kind, and every page carries the statement that they have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.
Second, the category is renaming itself. On 2026-09-16, the GLP-1-named product URLs at two of the largest sellers redirected to products no longer carrying "GLP-1" in the name, and four more GLP-1-named product URLs returned 404. That is a documented pattern, not an inference, and one of the renames is pleaded in a complaint filed in a federal court.
The two questions underneath this one
Most people searching for a patch are asking one of two things, and both have better pages than this one.
If the question is whether a non-injected option exists at all, it does, and it is approved: semaglutide is sold as a daily tablet, and orforglipron is a small molecule designed to be swallowed. We cover what those cost on GLP-1 pills and how the formats compare on the pill against the injection.
If the question is whether something over the counter can do this, the answer runs through the oral half of the same market — capsules rather than patches, which at least clear the statutory bar the patches do not. That evidence, including a 337-person randomised trial of the ingredient these products most often contain, is on GLP-1 supplements. And if the question is really about the body's own hormone rather than any product, the physiology is on natural GLP-1, where the operative number is that your own GLP-1 has a half-life of 1.5 to 2 minutes.
What would change this page
A human trial. Not a mouse study, not a formulation paper, and not a microneedle array reported as a patch. If a transdermal GLP-1 product is tested in people and the result is posted, this page will say so and will say what the result was. As of 2026-09-16 there is no such study registered.
Until then the position is the one the FTC wrote down in 2014, the chemistry has not moved, and the products have started changing their names.